SCHEMBL3085251

SCHEMBL3085251

OCc1cnn(Cc2ccccc2F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.63
L3MBTL1 Q9Y468 5/20 0.63
PKM P14618 2/20 0.63
MAPT P10636 1/20 0.63
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SCD O00767 2/20 0.44
SCD5 Q86SK9 2/20 0.44
ALK Q9UM73 1/20 0.42
POLB P06746 1/20 0.41
CYP19A1 P11511 1/20 0.41
KLKB1 P03952 1/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3091005 0.84 ALDH1A1 (0.63) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL15014102 0.84 L3MBTL1 (0.63) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL13181128 0.82 ALDH1A1 (0.60) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL3100268 0.82 KLKB1 (0.43) ALDH1A1L3MBTL1PKMMAPTALK
SCHEMBL16095711 0.81 ALDH1A1 (0.67) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL4790930 0.81 ALDH1A1 (0.44) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL13153145 0.81 ALDH1A1 (0.62) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL3097443 0.80 ALDH1A1 (0.55) ALDH1A1L3MBTL1PKMMAPTMEN1
SCHEMBL1244019 0.78 L3MBTL1 (0.61) L3MBTL1POLBCYP19A1ADORA2AADORA1
SCHEMBL15544649 0.78 ALDH1A1 (0.67) ALDH1A1L3MBTL1PKMMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101784520-B Novel malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2014-07-02 CN disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
CN-101784520-A Novel malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2010-07-21 CN disclosed
EP-1678181-B1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-12-31 EP disclosed
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
CN-1890241-A A2BAdenosine receptor antagonists CV THERAPEUTICS INC (US) 2007-01-03 CN disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 1178/4885L3MBTL1 2622/4885PKM 4149/4885
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 ALDH1A1 617/4885L3MBTL1 4273/4885PKM 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.